Crossject, a pharma company based in Dijon, France, is developing a needleless auto-injector device the company will use to deliver a portfolio of drugs including epinephrine.
The device consists of a specially designed glass tube that can withstand high pressure in combination with a propellant based on a nitrocellulose chemical reaction.
When activated, the device propels the drug under high pressure through the skin into the bloodstream without the need for a needle.
The company website provides the following description:
In a validation study, ZENEO® demonstrated its ability to ensure correct intramuscular injection regardless of the amount of fat underneath the skin. Thus, ZENEO® is the only system to offer full performance regardless of patient morphology.
Also, ZENEO® eliminates phobias and handling errors associated with classic needle-based auto-injectors.
The administration of the device requires two steps:
- Removal of the safety cap, which automatically breaks the sterility seal.
- Perpendicular placement of the device on the skin surface and a push; a click signal occurs once the injection is completed (in less than a tenth of a second).
We will follow up with Crossject to learn more about Zeneo and their timeline for introduction in the US.
Spokin Podcast Sparks Concern About Data: Theirs and Yours